Dendreon Corporation Inc. (DNDN) Announces Successful Phase III Prostate Impact Study
Source: http://Blog.QualityStocks.net/?p=15080Posted on Tuesday, April 14th, 2009 | In Market Commentary, Small & Micro Cap
In today’s pharmaceutical world, one needs to be fast off the mark. It is just a few hours old, but there may still be time to catch this one as investors make their choices. Prostate cancer treatment products are the next Lipitor, do your research and think about it.
Dendreon Corporation, a biotechnology company, works to develop and commercialize biotechnology therapeutics that enhance cancer treatment options. The company has several products in its product development pipeline with a prostate product making very successful progress in late stage approvals.
As we’ve stated in the past, there is a rush for larger pharmaceutical companies to refill their product pipelines. Although the supply of companies with later stage products, to fulfill this need, are growing smaller, there are still companies that fit the bill. Dendreon Corp. seems to be one of these companies as its prostate product makes solid headway toward approvals. Announced this morning, just ahead of the opening bell, the company’s prostate product is moving toward a quick approval.
As the company’s prostate product moves towards approval, the company has several other products that are in various states of development. Its current product pipeline includes a prostate cancer product for those men with limited options, an ”investigational Active Cellular Immunotherapy product” that has completed two Phase 1 testing and pre-clinical trials and products that include lung, colon and breast cancer options. As the market assesses the company’s progress, it does appear that there is opportunity if an investor can get there fast enough.
Let us hear your thoughts below:
Last 5 posts by QualityStocks
- Omnicity Corp. (OMCY.OB) Announces Addition of New Board Member - November 20th, 2009
- Muscle Flex, Inc. (MFLI.PK) Announces Release Time for the BUDDY Tablet Caddy Two-Minute Commercial and Landing Page - November 20th, 2009
- Artfest International, Inc. (ARTS.OB) Announces Revenue Profit Jumps - November 20th, 2009
- Omnicity Corp.’s (OMCY.OB) Recently-Issued Corporate Update - November 20th, 2009
- Soligenix Inc. (SNGX.OB) Taking Steps to Meet Challenges of Vaccine Technology and Biological Warfare - November 20th, 2009
Biotechnology, biotechnology therapeutics;, Breast Cancer, cancer, Cancer Treatment, cancer treatment products;, Dendreon Corp., Dendreon Corporation Inc.;, larger pharmaceutical, Market Commentary, Pharmaceutical World, Prostate Cancer, prostate cancer product;, prostate product;, Small & Micro Cap
 About QualityStocks (http://QualityStocks.net)
Our name, QualityStocks, emphasizes our commitment to connect subscribers with companies that have huge potential to succeed in the short and long-term future. We believe strong management and vision for the future are crucial for any company to be successful. Timing is everything and we help investors succeed by providing an objective, broad-based view of the SmallCap markets on a daily basis. Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.